Sponsors hope that a frequently-asked-questions commitment in the prescription drug user fee reauthorization will speed dissemination of US Food and Drug Administration thinking in the fast-moving cell and gene therapy sector.
As part of the upcoming PDUFA VII renewal, the Center for Biologics Evaluation and Research will publish and regularly update...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?